Share
.webp)
.webp)
.webp)
.webp)
Jeannette Jager-van Dijk
Arletta Pharma Solutions, a clinical-stage biopharmaceutical company developing therapies for women with Female Sexual Disorders (FSD), has appointed Jeannette Jager-van Dijk as Chief Executive Officer. Jager-van Dijk brings more than three decades of global pharmaceutical leadership experience across women’s health, vaccines, and specialty pharmaceuticals.
She assumes the role as Arletta advances plans for MONARCH, its proposed U.S. Phase 2 study of Lybrido™, an investigational on-demand, dual-action therapy for women with Female Sexual Interest/Arousal Disorder (FSIAD) and Hypoactive Sexual Desire Disorder (HSDD). The company recently received written feedback from the U.S. Food and Drug Administration (FDA) supporting core elements of the proposed study design and providing guidance on the potential future development pathway for Lybrido™.
As CEO, Jager-van Dijk will lead Arletta through the transition from regulatory alignment to clinical execution. Her responsibilities will include corporate strategy, clinical development, financing strategy, and engagement with U.S. investors, regulators, and potential strategic partners. The appointment also supports the company’s strategic focus on the United States as its principal regulatory and commercial market.
Jager-van Dijk previously held senior women’s health positions at Organon and its successors. Based in New Jersey, she was part of the Global Venture Team and led development, regulatory submission, and commercialization activities for Livial® in the United States and Japan.
She later served as Senior Director Marketing Europe Gynecology, leading European strategy for Livial®. She also served as Chair and spokesperson for the National Foundation for Education on Menopause in the Netherlands.
Most recently, Jager-van Dijk served as Global Marketing Director Drug Products at DSM Pharmaceuticals. Earlier, she spent nearly seven years at Crucell/Janssen, a Johnson & Johnson company, leading global marketing and commercial activities for vaccines across international markets.
